{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:49:34Z","timestamp":1792784974151,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This study was sponsored by Faron Pharmaceuticals Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mortality remains high after emergency open surgery for a ruptured abdominal aortic aneurysm (RAAA). The aim of the present study was to assess, if intravenous (IV) Interferon (IFN) beta-1a improve survival after surgery by up-regulating Cluster of differentiation (CD73). This is a multi-center phase II double-blind, 2:1 randomized, parallel group comparison of the efficacy and safety of IV IFN beta-1a vs. placebo for the prevention of death after open surgery for an infra-renal RAAA. All study patients presented a confirmed infra-renal RAAA, survived the primary emergency surgery and were treated with IFN beta-1a (10\u00a0\u03bcg) or matching placebo for 6\u00a0days after surgery. Major exclusion criteria included fatal hemorrhagic shock, chronic renal replacement therapy, diagnosed liver cirrhosis, severe congestive heart failure, advanced malignant disease, primary attempt of endovascular aortic repair (EVAR), and per-operative suprarenal clamping over 30\u00a0min. Main outcome measure was all-cause mortality at day 30 (D30) from initial emergency aortic reconstruction. The study was pre-maturely stopped due to a reported drug-drug interaction and was left under-powered. Out of 40 randomized patients 38 were included in the outcome analyses (27 IFN beta-1a and 11 placebo). There was no statistically significant difference between treatment groups at baseline except more open-abdomen and intestinal ischemia was present in the IFN beta-1a arm. D30 all-cause mortality was 22.2% (6\/27) in the IFN beta-1a arm and 18.2% (2\/11) in the placebo arm (OR 1.30; 95% CI 0.21\u20138.19). The most common adverse event relating to the IFN beta-1a was pyrexia (20.7% in the IFN beta-1a arm vs. 9.1% in the placebo arm). Patients with high level of serum CD73 associated with survival (P\u2009=\u20090.001) whereas the use of glucocorticoids and the presence of IFN beta-1a neutralizing antibodies associated with a poor CD73 response and survival. The initial aim of the trial, if postoperative INF beta-1a treatment results on better RAAA survival, could not be demonstrated. Nonetheless the anticipated target mechanism up-regulation of CD73 was associated with 100% survival. According to present results the INF beta-1a induced up-regulation of serum CD73 was blocked with both use of glucocorticoids and serum IFN beta-1a neutralizing antibodies. The study was pre-maturely stopped due to interim analysis after a study concerning the use if IV IFN beta-1a in ARDS suggested that the concomitant use of glucocorticoids and IFN beta-1a block the CD73 induction.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial registration:<\/jats:bold>\n                    ClinicalTrials.gov NCT03119701. Registered 19\/04\/2017 (retrospectively registered).\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-05771-1","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T06:05:49Z","timestamp":1643868349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Induction of CD73 prevents death after emergency open aortic surgery for a ruptured abdominal aortic aneurysm: a randomized, double-blind, placebo-controlled study"],"prefix":"10.1038","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct03119701","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Harri","family":"Hakovirta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juho","family":"Jalkanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eija","family":"Saimanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiia","family":"Kukkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pekka","family":"Romsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velipekka","family":"Suominen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Vikatmaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Valtonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti K.","family":"Karvonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarit","family":"Venermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"INFORAAA Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harri","family":"Hakovirta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juho","family":"Jalkanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eija","family":"Saimanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiia","family":"Kukkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pekka","family":"Romsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velipekka","family":"Suominen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Vikatmaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Valtonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti K.","family":"Karvonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarit","family":"Venermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veikko","family":"Nikulainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Erik","family":"Wickstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimmo","family":"Kaskinoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pirkka","family":"Vikatmaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilkka","family":"Kantonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riikka","family":"Tulamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilkka","family":"Uurto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damir","family":"Vakhitov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Pokela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjaleena","family":"Ilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"M\u00e4enp\u00e4\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miikka","family":"Frant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Pihlaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha","family":"Koskenkari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyrki","family":"Virkkunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raili","family":"Laru-Sompa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anni","family":"Pulkkinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannu","family":"Savolainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"M\u00e4kel\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seppo","family":"Hovilehto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asser","family":"Aavik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcri","family":"Lieberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geidi","family":"Rajaste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaak","family":"Kals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrus","family":"Metsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toomas","family":"Ellervee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heli","family":"J\u00e4rve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silver","family":"Sarapuu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadri","family":"Tamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linas","family":"Velicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martynas","family":"Laukaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadas","family":"Lenkutis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerijus","family":"Misonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrida","family":"Asekiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arminas","family":"Skrebunas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gintautas","family":"Kekstas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"5771_CR1","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/bjs.10200","volume":"103","author":"MT Laine","year":"2016","unstructured":"Laine, M. T., Laukontaus, S. J., Kantonen, I. & Venermo, M. Population-based study of ruptured abdominal aortic aneurysm. Br. J. Surg. 103, 1634\u20131639 (2016).","journal-title":"Br. J. Surg."},{"key":"5771_CR2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.ejvs.2014.03.003","volume":"47","author":"SC van Beek","year":"2014","unstructured":"van Beek, S. C., Conijn, A. P., Koelemay, M. J. & Balm, R. Editor\u2019s choice\u2014Endovascular aneurysm repair versus open repair for patients with a ruptured abdominal aortic aneurysm: A systematic review and meta-analysis of short-term survival. Eur. J. Vasc. Endovasc. Surg. 47, 593\u2013602 (2014).","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"5771_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ejvs.2018.06.002","volume":"56","author":"BO Patterson","year":"2018","unstructured":"Patterson, B. O., O\u2019Donnell, T. F. X., Kolh, P., Holt, P. J. E. & Schermerhorn, M. Improved outcomes for ruptured abdominal aortic aneurysm through centralisation. Eur. J. Vasc. Endovasc. Surg. 56, 159\u2013160 (2018).","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"5771_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ejvs.2018.01.014","volume":"56","author":"J Budtz-Lilly","year":"2018","unstructured":"Budtz-Lilly, J. et al. Editor\u2019s choice\u2014The impact of centralisation and endovascular aneurysm repair on treatment of ruptured abdominal aortic aneurysms based on international registries. Eur. J. Vasc. Endovasc. Surg. 56, 181\u2013188 (2018).","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"5771_CR5","doi-asserted-by":"publisher","first-page":"4859","DOI":"10.1136\/bmj.j4859","volume":"359","author":"IMPROVE Trial Investigators","year":"2017","unstructured":"IMPROVE Trial Investigators. Comparative clinical effectiveness and cost effectiveness of endovascular strategy v open repair for ruptured abdominal aortic aneurysm: Three year results of the IMPROVE randomised trial. BMJ 359, 4859 (2017).","journal-title":"BMJ"},{"key":"5771_CR6","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1161\/CIRCRESAHA.116.305715","volume":"116","author":"J Jalkanen","year":"2015","unstructured":"Jalkanen, J. et al. Aberrant circulating levels of purinergic signaling markers are associated with several key aspects of peripheral atherosclerosis and thrombosis. Circ. Res. 116, 1206\u20131215 (2015).","journal-title":"Circ. Res."},{"key":"5771_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11302-016-9545-0","volume":"13","author":"J Jalkanen","year":"2017","unstructured":"Jalkanen, J., Hollmen, M., Jalkanen, S. & Hakovirta, H. Regulation of CD73 in the development of lower limb atherosclerosis. Purinergic Signal 13, 127\u2013134 (2017).","journal-title":"Purinergic Signal"},{"key":"5771_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1161\/ATVBAHA.119.313002","volume":"40","author":"NR Sutton","year":"2020","unstructured":"Sutton, N. R. et al. CD73 promotes age-dependent accretion of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 40, 61\u201371 (2020).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"5771_CR9","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1084\/jem.20040915","volume":"200","author":"LF Thompson","year":"2004","unstructured":"Thompson, L. F. et al. Crucial role for ecto-5\u2019-nucleotidase (CD73) in vascular leakage during hypoxia. J. Exp. Med. 200, 1395\u20131405 (2004).","journal-title":"J. Exp. Med."},{"key":"5771_CR10","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1056\/NEJMra1205750","volume":"367","author":"HK Eltzschig","year":"2012","unstructured":"Eltzschig, H. K., Sitkovsky, M. V. & Robson, S. C. Purinergic signaling during inflammation. N. Engl. J. Med. 367, 2322\u20132333 (2012).","journal-title":"N. Engl. J. Med."},{"key":"5771_CR11","doi-asserted-by":"publisher","first-page":"C1079","DOI":"10.1152\/ajpcell.00285.2019","volume":"317","author":"M Minor","year":"2019","unstructured":"Minor, M., Alcedo, K. P., Battaglia, R. A. & Snider, N. T. Cell type- and tissue-specific functions of ecto-5\u2019-nucleotidase (CD73). Am. J. Physiol. Cell Physiol. 317, C1079\u2013C1092 (2019).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"5771_CR12","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1002\/eji.200737793","volume":"37","author":"J Kiss","year":"2007","unstructured":"Kiss, J. et al. IFN-beta protects from vascular leakage via up-regulation of CD73. Eur. J. Immunol. 37, 3334\u20133338 (2007).","journal-title":"Eur. J. Immunol."},{"key":"5771_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S2213-2600(13)70259-5","volume":"2","author":"G Bellingan","year":"2014","unstructured":"Bellingan, G. et al. The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: An open-label study. Lancet Respir. Med. 2, 98\u2013107 (2014).","journal-title":"Lancet Respir. Med."},{"key":"5771_CR14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s13054-020-03048-5","volume":"24","author":"J Jalkanen","year":"2020","unstructured":"Jalkanen, J., Hollmen, M. & Jalkanen, S. Interferon beta-1a for COVID-19: Critical importance of the administration route. Crit. Care 24, 335 (2020).","journal-title":"Crit. Care"},{"key":"5771_CR15","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1001\/jama.2019.22525","volume":"323","author":"VM Ranieri","year":"2020","unstructured":"Ranieri, V. M. et al. Effect of intravenous interferon beta-1a on death and days free from mechanical ventilation among patients with moderate to severe acute respiratory distress syndrome: A randomized clinical trial. JAMA 323, 725\u2013733 (2020).","journal-title":"JAMA"},{"key":"5771_CR16","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00134-020-06086-3","volume":"46","author":"J Jalkanen","year":"2020","unstructured":"Jalkanen, J., Pettila, V., Huttunen, T., Hollmen, M. & Jalkanen, S. Glucocorticoids inhibit type I IFN beta signaling and the upregulation of CD73 in human lung. Intens. Care Med. 46, 1937\u20131940 (2020).","journal-title":"Intens. Care Med."},{"key":"5771_CR17","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1016\/S0140-6736(20)32132-2","volume":"396","author":"J Carlet","year":"2020","unstructured":"Carlet, J., Payen, D. & Opal, S. M. Steroids for sepsis and ARDS: This eternal controversy remains with COVID-19. Lancet 396, e61\u2013e62 (2020).","journal-title":"Lancet"},{"key":"5771_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.it.2020.11.003","volume":"42","author":"V Feuillet","year":"2021","unstructured":"Feuillet, V., Canard, B. & Trautmann, A. Combining antivirals and immunomodulators to fight COVID-19. Trends Immunol. 42, 31\u201344 (2021).","journal-title":"Trends Immunol."},{"key":"5771_CR19","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1093\/rheumatology\/kez078","volume":"58","author":"E Huijser","year":"2019","unstructured":"Huijser, E. et al. MxA is a clinically applicable biomarker for type I interferon activation in systemic lupus erythematosus and systemic sclerosis. Rheumatology (Oxford) 58, 1302\u20131303 (2019).","journal-title":"Rheumatology (Oxford)"},{"key":"5771_CR20","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1212\/WNL.58.12.1786","volume":"58","author":"AM Vallittu","year":"2002","unstructured":"Vallittu, A. M. et al. Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients. Neurology 58, 1786\u20131790 (2002).","journal-title":"Neurology"},{"key":"5771_CR21","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1126\/science.abd4570","volume":"370","author":"Q Zhang","year":"2020","unstructured":"Zhang, Q. et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370, 4570 (2020).","journal-title":"Science"},{"key":"5771_CR22","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1126\/scitranslmed.abh2624","volume":"13","author":"MGP van der Wijst","year":"2021","unstructured":"van der Wijst, M. G. P. et al. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci. Transl. Med. 13, 2624 (2021).","journal-title":"Sci. Transl. Med."},{"key":"5771_CR23","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1681\/ASN.2006101141","volume":"18","author":"A Grenz","year":"2007","unstructured":"Grenz, A. et al. Protective role of ecto-5\u2019-nucleotidase (CD73) in renal ischemia. J. Am. Soc. Nephrol. 18, 833\u2013845 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"5771_CR24","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1161\/CIRCULATIONAHA.106.669697","volume":"115","author":"T Eckle","year":"2007","unstructured":"Eckle, T. et al. Cardioprotection by ecto-5\u2019-nucleotidase (CD73) and A2B adenosine receptors. Circulation 115, 1581\u20131590 (2007).","journal-title":"Circulation"},{"key":"5771_CR25","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.4049\/jimmunol.0903617","volume":"186","author":"ML Hart","year":"2011","unstructured":"Hart, M. L. et al. Hypoxia-inducible factor-1alpha-dependent protection from intestinal ischemia\/reperfusion injury involves ecto-5\u2019-nucleotidase (CD73) and the A2B adenosine receptor. J. Immunol. 186, 4367\u20134374 (2011).","journal-title":"J. Immunol."},{"key":"5771_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1161\/ATVBAHA.107.153130","volume":"28","author":"S Jalkanen","year":"2008","unstructured":"Jalkanen, S. & Salmi, M. VAP-1 and CD73, endothelial cell surface enzymes in leukocyte extravasation. Arterioscler. Thromb. Vasc. Biol. 28, 18\u201326 (2008).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"5771_CR27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1161\/CIRCULATIONAHA.116.021311","volume":"134","author":"H Liu","year":"2016","unstructured":"Liu, H. et al. Beneficial role of erythrocyte adenosine A2B receptor-mediated AMP-activated protein kinase activation in high-altitude hypoxia. Circulation 134, 405\u2013421 (2016).","journal-title":"Circulation"},{"key":"5771_CR28","doi-asserted-by":"publisher","first-page":"17462","DOI":"10.1073\/pnas.1317158110","volume":"110","author":"Z Cai","year":"2013","unstructured":"Cai, Z., Luo, W., Zhan, H. & Semenza, G. L. Hypoxia-inducible factor 1 is required for remote ischemic preconditioning of the heart. Proc. Natl. Acad. Sci. U.S.A. 110, 17462\u201317467 (2013).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"5771_CR29","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1056\/NEJMe1509718","volume":"373","author":"DJ Hausenloy","year":"2015","unstructured":"Hausenloy, D. J. & Yellon, D. M. Targeting myocardial reperfusion injury\u2014The search continues. N. Engl. J. Med. 373, 1073\u20131075 (2015).","journal-title":"N. Engl. J. Med."},{"key":"5771_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008493.pub2","author":"OJ Liakopoulos","year":"2012","unstructured":"Liakopoulos, O. J., Kuhn, E. W., Slottosch, I., Wassmer, G. & Wahlers, T. Preoperative statin therapy for patients undergoing cardiac surgery. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD008493.pub2 (2012).","journal-title":"Cochrane Database Syst. Rev."},{"key":"5771_CR31","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1161\/hh0402.105668","volume":"90","author":"S Ledoux","year":"2002","unstructured":"Ledoux, S. et al. Lovastatin enhances ecto-5\u2019-nucleotidase activity and cell surface expression in endothelial cells: Implication of rho-family GTPases. Circ. Res. 90, 420\u2013427 (2002).","journal-title":"Circ. Res."},{"key":"5771_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejvs.2003.09.005","volume":"27","author":"MJ Bown","year":"2004","unstructured":"Bown, M. J. et al. The post-operative mortality of ruptured abdominal aortic aneurysm repair. Eur. J. Vasc. Endovasc. Surg. 27, 65\u201374 (2004).","journal-title":"Eur. J. Vasc. Endovasc. Surg."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05771-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05771-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05771-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T17:11:12Z","timestamp":1669309872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05771-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["5771"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-05771-1","relation":{"has-review":[{"id-type":"doi","id":"10.32388\/8XRFG8","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-732466\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-732466\/v2","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,3]]},"assertion":[{"value":"23 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Jalkanen and Karvonen own stock and are employed by Faron Pharmaceuticals Ltd. Other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1839"}}